ECR 2025: Esaote Group presents Integrated Medical Imaging Solutions and unveils innovations in Ultrasound Technology
Ebit showcases SUITESTENSA ZEfiRO: the new "cloud-native" PACS with diagnostic viewer VIENNA, Feb. 26, 2025 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic resonance and medical IT - presents its new portfolio of imaging solutions at the European Congress of Radiology (ECR) (Vienna, February 26 /March...
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharma Industrial"), has received approval from the National Medical Products Administration ("NMPA") for the New Drug Application ("NDA") for...
RESPIREE SECURES SINGAPORE HSA CLEARANCE FOR PEDIATRIC EXPANSION OF CARDIO-RESPIRATORY WEARABLE AND FOR ITS NEW EHR STREAMLINED PLATFORM
SINGAPORE, Feb. 26, 2025 /PRNewswire/ -- AI/ML health tech startup Respiree has received clearance from the Health Sciences Authority (HSA) to extend its RS001 cardio-respiratory wearable to pediatric populations. This clearance also enables the extension of Respiree's software platform, introducing enterprise-grade pathway management services and EHR interoperability which further enhances its innovative healthcare...
Ping An Health Launches “Ping An Xin Yi” AI Doctor Assistant Service to Enhance Accessibility and Satisfaction in Medical Services
HONG KONG and SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) recently announced the launch of "Ping An Xin Yi," an AI-powered digital doctor service integrated within its Ping An Health APP. This innovative service offers 24/7 access to AI-assisted health consultations, expanding the...
Waterdrop Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 12, 2025
BEIJING, Feb. 26, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before U.S. markets open on Wednesday, March 12, 2025. Waterdrop's management team will...
E-Health Now Founder & CEO Kelly Xu was honored as the “2024 Forbes China Emerging Innovator and Entrepreneur”
BEIJING, Feb. 26, 2025 /PRNewswire/ -- On February 22, 2025, the Forbes China Emerging Innovators and Entrepreneurs Forum and Awards Ceremony was held at the Shangri La Hotel in Hangzhou. This grand event of innovation and entrepreneurship brought together entrepreneurs, investors, and industry experts from all walks of life to explore global innovation trends. In the highly anticipated Award Ceremony, Kelly...
Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes
Kim, M. C., Yun, S. C., Lee, H. B., Lee, P. H., Lee, S. W., Choi, S. H., Kim, Y. S., Woo, J. H., Kim, S. H., & Kwon, S. U. (2017). Herpes Zoster Increases the Risk of Stroke and Myocardial Infarction. Journal of the American College of Cardiology, 70(2), 295–296. https://doi.org/10.1016/j.jacc.2017.05.015 Giorda, C. B., Picariello, R.,...
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
MELBOURNE, Australia, Feb. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its breakthrough investigational kidney cancer PET imaging agent TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), granted a Priority Review and...
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Feb. 26, 2025 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders. Under the agreement, the partner...
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
Data confirms significant clinical and endoscopic benefits of etrasimod 2mg after 40 weeks of maintenance treatment Etrasimod demonstrates robust efficacy across multiple endpoints, including mucosal healing, endoscopic normalization, and histological remission Safety profile remains consistent with previous studies, with no new safety findings were observed SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or...
